Skip to main content
Medicenna Therapeutics Corp. logo

Medicenna Therapeutics Corp. — Investor Relations & Filings

Ticker · MDNA TSX Professional, scientific and technical activities
Open in API
Filings indexed 229 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country CA Canada
Listing TSX MDNA

About Medicenna Therapeutics Corp.

https://www.medicenna.com/

Medicenna Therapeutics Corp. is a clinical-stage immunotherapy company focused on developing novel, highly selective engineered cytokines known as Superkines. These proprietary therapies are designed to overcome the limitations of unmodified interleukins by enhancing specificity, function, and safety profiles. Superkines modulate, fine-tune, or amplify the immune system to fight disease. Medicenna's initial focus is on developing super-agonists and antagonists based on interleukin-2 (IL-2), IL-4, and IL-13. The company is building a pipeline of programs targeting advanced cancers, autoimmune, and neuroinflammatory diseases, aiming to deliver potential best-in-class immunotherapies.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings
2026-04-21 English
News release - English.pdf
Regulatory Filings Classification · 1% confidence The document is a corporate press release announcing new preclinical safety and efficacy data for a drug candidate (MDNA113) to be presented at a scientific conference. It contains forward-looking statements, R&D details, and contact information, but no financial results, management changes, dividend, or other structured filing content. It does not represent an earnings report, annual/interim report, proxy, or technical investor presentation but is a general regulatory news announcement. Therefore, it falls into the fallback category for miscellaneous regulatory announcements.
2026-04-21 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a corporate press release announcing that the company’s CEO will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference, including details on date, time, location, and webcast information. There is no full financial report, transcript, or voting information. It is an investor relations communication about an upcoming presentation, which best fits the “Investor Presentation” category (Code: IP).
2026-04-14 English
News release - English.pdf
Investor Presentation Classification · 1% confidence The document is a press release announcing that Medicenna’s CEO will present at the 2026 Bloom Burton & Co. Healthcare Investor Conference. It provides details on the date, time, location, webcast link and a corporate update aimed at investors. This fits the “Investor Presentation” category rather than an actual financial report, earnings release, or proxy. Therefore, it should be classified as an Investor Presentation (IP).
2026-04-14 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing the appointment of a new Chief Medical Officer, describing her background and role. This constitutes an announcement of a change in senior management, fitting the Board/Management Information category.
2026-04-09 English
News release - English.pdf
Board/Management Information Classification · 1% confidence The document is a press release announcing the appointment of Dr. Nageatte Ibrahim as Chief Medical Officer, which is a senior management change. It does not present financial results or request votes, nor is it a full report. Therefore, it fits the Board/Management Information category (MANG).
2026-04-09 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.